January 5, 2017 / 12:33 PM / a year ago

Halozyme's pancreatic cancer drug succeeds in mid-stage trial

Jan 5 (Reuters) - Halozyme Therapeutics Inc said its lead drug to treat a late form of pancreated cancer met the main goal in a mid-stage study, sending its shares soaring in premarket trading.

The study population showed a statistically significant increase in progression-free survival, the company said.

Pancreatic cancer is the third-leading cause of cancer-related death in the United States.

Halozyme’s shares were up 44 percent at $15.40 in trading before the opening bell on Thursday. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Ted Kerr)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below